Global Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035
- Published Date : October 25, 2025
- Updated On : April 9, 2026
- Pages : 157
Global Non-Small Cell Lung Cancer Market Outlook
Thelansis’s “Global Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Small Cell Lung Cancer treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Non-Small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is the most prevalent lung malignancy, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, driven by diverse oncogenic alterations including EGFR mutations, ALK and ROS1 rearrangements, KRAS G12C mutations, MET exon 14 skipping, RET fusions, and BRAF V600E mutations alongside PD-L1 overexpression. Tobacco smoking remains the dominant risk factor, though never-smoker adenocarcinoma with targetable driver mutations represents a growing subpopulation. Patients present with persistent cough, haemoptysis, dyspnoea, and constitutional symptoms, with many diagnosed at advanced stages. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis. Pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy addresses lower expressors. EGFR-mutated disease is addressed with osimertinib monotherapy or the amivantamab plus lazertinib combination, including a recently approved subcutaneous formulation, which has fundamentally redefined frontline standards by delivering superior progression-free survival over monotherapy. ALK is addressed with alectinib, ROS1 with entrectinib, KRAS G12C with adagrasib, MET with tepotinib, RET with selpercatinib, and BRAF V600E with dabrafenib-trametinib. Surgical resection remains curative for localised disease, with adjuvant osimertinib improving survival in resected EGFR-mutated NSCLC. Prognosis varies markedly with stage and molecular subtype; multidisciplinary management, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Global Non-Small Cell Lung Cancer Market Outlook
Thelansis’s “Global Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Small Cell Lung Cancer treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Non-Small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is the most prevalent lung malignancy, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, driven by diverse oncogenic alterations including EGFR mutations, ALK and ROS1 rearrangements, KRAS G12C mutations, MET exon 14 skipping, RET fusions, and BRAF V600E mutations alongside PD-L1 overexpression. Tobacco smoking remains the dominant risk factor, though never-smoker adenocarcinoma with targetable driver mutations represents a growing subpopulation. Patients present with persistent cough, haemoptysis, dyspnoea, and constitutional symptoms, with many diagnosed at advanced stages. Comprehensive next-generation sequencing and PD-L1 immunohistochemistry are mandatory at diagnosis. Pembrolizumab monotherapy is standard for high PD-L1 expressors, while chemoimmunotherapy addresses lower expressors. EGFR-mutated disease is addressed with osimertinib monotherapy or the amivantamab plus lazertinib combination, including a recently approved subcutaneous formulation, which has fundamentally redefined frontline standards by delivering superior progression-free survival over monotherapy. ALK is addressed with alectinib, ROS1 with entrectinib, KRAS G12C with adagrasib, MET with tepotinib, RET with selpercatinib, and BRAF V600E with dabrafenib-trametinib. Surgical resection remains curative for localised disease, with adjuvant osimertinib improving survival in resected EGFR-mutated NSCLC. Prognosis varies markedly with stage and molecular subtype; multidisciplinary management, smoking cessation, and patient-centred supportive care are integral to optimising outcomes.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)